NCT00549055View on ClinicalTrials.gov

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Macugen

Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)

Trial Locations (4)

2100

Pfizer Investigational Site, Deurne

3000

Pfizer Investigational Site, Leuven

3200

Pfizer Investigational Site, Aarschot

4000

Pfizer Investigational Site, Liège

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY